PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company’s proprietary Versamune® T-cell activating technology,
announced today that its management team will present at several
investor conferences listed below during the third quarter of
2021.
At the recent American Society of Clinical Oncology (ASCO) 2021
Annual Meeting, interim data was presented in an oral session on
PDS Biotech’s lead asset, PDS0101, in combination with two
investigational immune-modulating agents being studied in two
groups of advanced cancer patients. In the first group of patients
who had failed treatment with chemotherapy and radiation, tumor
reduction (objective response) was seen in 83% (5 of 6) of
patients. In the second group, patients who in addition had failed
treatment with checkpoint inhibitors, tumor reduction was seen in
58% (7 of 12) patients.
PDS0101 (Versamune®-HPV16) is an investigational immunotherapy
candidate designed to treat cancers caused by infection with HPV16
(HPV16-positive cancers) by activating the immune system to produce
in vivo CD8+ (killer) T-cells to target and kill tumors that are
HPV16-positive. Analyses of immune responses and other immune
correlates are ongoing.
The upcoming investor conferences will offer leadership the
opportunity to provide an update on both ongoing PDS0101 Phase 2
clinical trials, as well as preparations to move two other
investigational compounds PDS0102 (Versamune®-TARP) and PDS0103
(Versamune®-MUC1) into human testing. The conference details are as
follows:
BTIG Investor ConferenceDate: Tuesday, August 10, 2021
HC Wainwright 23rd Annual Global Investment ConferenceDate:
Tuesday, September 14, 2021
Cantor Healthcare ConferenceDate: Monday, September 27, 2021
AGP Fall Virtual Biotech & Specialty Pharma ConferenceDate:
Wednesday, October 13, 2021
A separate press release will be issued once presentation times
become available.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing
a growing pipeline of cancer immunotherapies based on the Company’s
proprietary Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the
immune system to better recognize diseased cells and effectively
attack and destroy them. The company’s pipeline products address
various cancers including breast, colon, lung, prostate and ovarian
cancers. To learn more, please visit www.pdsbiotech.com or follow
us on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech’s lead candidate, PDS0101, combines the utility of
the Versamune® platform with targeted antigens in HPV-expressing
cancers. In partnership with Merck & Co., PDS Biotech is
evaluating a combination of PDS0101 and KEYTRUDA® in a Phase 2
study in first-line treatment of recurrent or metastatic head and
neck cancer. PDS Biotech is also conducting two additional Phase 2
studies in advanced HPV-associated cancers and advanced localized
cervical cancer with the National Cancer Institute (NCI) and The
University of Texas MD Anderson Cancer Center, respectively.
Forward Looking Statements
This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States
Securities Exchange Act of 1934, as amended, and Section 27A of the
United States Securities Act of 1933, as amended) concerning PDS
Biotechnology Corporation (the “Company”) and other matters. These
statements may discuss goals, intentions and expectations as to
future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company’s
management, as well as assumptions made by, and information
currently available to, management. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “expect,”
“anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,”
“intend,” “forecast,” “guidance”, “outlook” and other similar
expressions among others. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the Company’s ability to protect its
intellectual property rights; the Company’s anticipated capital
requirements, including the Company’s anticipated cash runway and
the Company’s current expectations regarding its plans for future
equity financings; the Company’s dependence on additional financing
to fund its operations and complete the development and
commercialization of its product candidates, and the risks that
raising such additional capital may restrict the Company’s
operations or require the Company to relinquish rights to the
Company’s technologies or product candidates; the Company’s limited
operating history in the Company’s current line of business, which
makes it difficult to evaluate the Company’s prospects, the
Company’s business plan or the likelihood of the Company’s
successful implementation of such business plan; the timing for the
Company or its partners to initiate the planned clinical trials for
PDS0101, PDS0203 and other Versamune® based products; the future
success of such trials; the successful implementation of the
Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101, PDS0203 and
other Versamune® based products and the Company’s interpretation of
the results and findings of such programs and collaborations and
whether such results are sufficient to support the future success
of the Company’s product candidates; the success, timing and cost
of the Company’s ongoing clinical trials and anticipated clinical
trials for the Company’s current product candidates, including
statements regarding the timing of initiation, pace of enrollment
and completion of the trials (including our ability to fully fund
our disclosed clinical trials, which assumes no material changes to
our currently projected expenses), futility analyses, presentations
at conferences and data reported in an abstract, and receipt of
interim results, which are not necessarily indicative of the final
results of the Company’s ongoing clinical trials; any Company
statements about its understanding of product candidates mechanisms
of action and interpretation of preclinical and early clinical
results from its clinical development programs and any
collaboration studies; the acceptance by the market of the
Company’s product candidates, if approved; the timing of and the
Company’s ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company’s product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company’s control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company’s
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
Media & Investor Relations Contacts
Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404) 736-3838 Email:
rich@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024